Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2023)
Fortrea Holdings (FTRE) reported Restructuring Costs of $7.6 million for Q4 2023, up 181.48% on a YoY basis from $2.7 million in Q4 2022, and down 34.48% quarter-over-quarter from $11.6 million in Q3 2023.
Fortrea Holdings (FTRE) Restructuring Costs (2022 - 2023) Analysis & Trends
Fortrea Holdings has reported Restructuring Costs for 2 years, with the latest figure at $7.6 million in Q4 2023.
- For the quarter ending Q4 2023, Restructuring Costs rose 181.48% year-over-year to $7.6 million; the trailing twelve-month figure through Dec 2023 stood at $25.8 million (changed N/A YoY), and the FY2023 full-year result was $24.3 million, down 20.33% from the prior year.
- Restructuring Costs for Q4 2023 stood at $7.6 million, down from $11.6 million in the prior quarter.
- The five-year high for Restructuring Costs was $13.0 million in Q2 2022, with the low at $2.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 11.60 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Dec 31, 2022 | 2.70 Mn |
| Sep 30, 2022 | 5.20 Mn |
| Jun 30, 2022 | 13.00 Mn |